| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alexander K Song, Kaitlyn R Hay, Paula Trujillo, Megan Aumann, Adam J Stark, Yan Yan, Hakmook Kang, Manus J Donahue, David H Zald, Daniel O Claasse. Amphetamine-induced dopamine release and impulsivity in Parkinson disease. Brain : a journal of neurology. 2021-12-24. PMID:34951464. |
we hypothesized that parkinson disease patients with impulsive-compulsive behaviors would have greater ventral striatal dopaminergic response to dextroamphetamine, and that an inability to attenuate ventral striatal dopamine release via midbrain d2 autoreceptors would underlie this response. |
2021-12-24 |
2023-08-13 |
human |
| Myung Jun Lee, Kyoungjune Pak, Han-Kyeol Kim, Kelly N Nudelman, Jong Hun Kim, Yun Hak Kim, Junho Kang, Min Seok Baek, Chul Hyoung Lyo. Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease. NPJ Parkinson's disease. vol 7. issue 1. 2021-12-11. PMID:34836969. |
genetic factors affecting dopaminergic deterioration during the premotor stage of parkinson disease. |
2021-12-11 |
2023-08-13 |
Not clear |
| Myung Jun Lee, Kyoungjune Pak, Han-Kyeol Kim, Kelly N Nudelman, Jong Hun Kim, Yun Hak Kim, Junho Kang, Min Seok Baek, Chul Hyoung Lyo. Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease. NPJ Parkinson's disease. vol 7. issue 1. 2021-12-11. PMID:34836969. |
to estimate dopaminergic dysfunction in patients with parkinson disease (pd) during the premotor stage and to investigate the effect of genetic factors on the trajectories. |
2021-12-11 |
2023-08-13 |
Not clear |
| Emma V Rusilowicz-Jones, Francesco G Barone, Fernanda Martins Lopes, Elezabeth Stephen, Heather Mortiboys, Sylvie Urbé, Michael J Clagu. Benchmarking a highly selective USP30 inhibitor for enhancement of mitophagy and pexophagy. Life science alliance. vol 5. issue 2. 2021-11-30. PMID:34844982. |
in dopaminergic neurons, generated from parkinson disease patients carrying loss of function prkn mutations, compound 39 could significantly restore mitophagy to a level approaching control values. |
2021-11-30 |
2023-08-13 |
Not clear |
| Osama F Elabi, Jeffrey S Davies, Emma L Lan. L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease. International journal of molecular sciences. vol 22. issue 22. 2021-11-29. PMID:34830228. |
l-dopa-dependent effects of glp-1r agonists on the survival of dopaminergic cells transplanted into a rat model of parkinson disease. |
2021-11-29 |
2023-08-13 |
rat |
| Daniel A Xu, Timothy P DeYoung, Nicholas P Kondoleon, Roderic G Eckenhoff, Maryellen F Eckenhof. Anesthetic Effects on the Progression of Parkinson Disease in the Rat DJ-1 Model. Anesthesia and analgesia. vol 133. issue 5. 2021-11-22. PMID:34673725. |
parkinson disease is a chronic and progressive movement disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (snpc). |
2021-11-22 |
2023-08-13 |
rat |
| Beatrice Ana-Maria Anghelescu, Raluca Todoran, Cinthia Terroba-Chambi, Veronica Brun. Antidepressants Effects on Pain in Parkinson Disease: A Systematic Review. Clinical neuropharmacology. vol 44. issue 6. 2021-11-16. PMID:34767324. |
pain in parkinson disease (pd) is complex as this symptom can be multifactorial in origin because deficits in dopaminergic but also other neurotransmitters are involved. |
2021-11-16 |
2023-08-13 |
Not clear |
| Tamara Pringsheim, Gregory S Day, Don B Smith, Alex Rae-Grant, Nicole Licking, Melissa J Armstrong, Rob M A de Bie, Emmanuel Roze, Janis M Miyasaki, Robert A Hauser, Alberto J Espay, Justin P Martello, Julie A Gurwell, Lori Billinghurst, Kelly Sullivan, Michael S Fitts, Nicholas Cothros, Deborah A Hall, Miriam Rafferty, Lynn Hagerbrant, Tara Hastings, Mary Dolan O'Brien, Heather Silsbee, Gary Gronseth, Anthony E Lan. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. vol 97. issue 20. 2021-11-16. PMID:34782410. |
dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a report of the aan guideline subcommittee. |
2021-11-16 |
2023-08-13 |
Not clear |
| Tamara Pringsheim, Gregory S Day, Don B Smith, Alex Rae-Grant, Nicole Licking, Melissa J Armstrong, Rob M A de Bie, Emmanuel Roze, Janis M Miyasaki, Robert A Hauser, Alberto J Espay, Justin P Martello, Julie A Gurwell, Lori Billinghurst, Kelly Sullivan, Michael S Fitts, Nicholas Cothros, Deborah A Hall, Miriam Rafferty, Lynn Hagerbrant, Tara Hastings, Mary Dolan O'Brien, Heather Silsbee, Gary Gronseth, Anthony E Lan. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. vol 97. issue 20. 2021-11-16. PMID:34782410. |
to review the current evidence on the options available for initiating dopaminergic treatment of motor symptoms in early-stage parkinson disease and provide recommendations to clinicians. |
2021-11-16 |
2023-08-13 |
Not clear |
| Howard D Weiss, Laura Mars. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurology. Clinical practice. vol 2. issue 4. 2021-10-21. PMID:23634371. |
impulse control disorders and compulsive behaviors associated with dopaminergic therapies in parkinson disease. |
2021-10-21 |
2023-08-12 |
Not clear |
| Howard D Weiss, Laura Mars. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurology. Clinical practice. vol 2. issue 4. 2021-10-21. PMID:23634371. |
impulse control disorders (icd) (most commonly pathologic gambling, hypersexuality, and uncontrollable spending) and compulsive behaviors can be triggered by dopaminergic therapies in parkinson disease (pd). |
2021-10-21 |
2023-08-12 |
Not clear |
| Y J Bae, Y S Song, J-M Kim, B S Choi, Y Nam, J-H Choi, W W Lee, J H Ki. Determining the Degree of Dopaminergic Denervation Based on the Loss of Nigral Hyperintensity on SMWI in Parkinsonism. AJNR. American journal of neuroradiology. vol 42. issue 4. 2021-10-12. PMID:33509919. |
nigrostriatal dopaminergic function in patients with parkinson disease can be assessed using |
2021-10-12 |
2023-08-13 |
Not clear |
| Caroline M Tanne. Exploring the clinical burden of OFF periods in Parkinson disease. The American journal of managed care. vol 26. issue 12 Suppl. 2021-09-24. PMID:33058688. |
characterized pathologically by degeneration of dopaminergic neurons, with widespread pathology in nondopaminergic systems, parkinson disease leads to an array of motor and nonmotor symptoms that can significantly impact an affected individual's quality of life. |
2021-09-24 |
2023-08-13 |
Not clear |
| Tanya Simuni, Brian Fiske, Kalpana Merchant, Christopher S Coffey, Elizabeth Klingner, Chelsea Caspell-Garcia, David-Erick Lafontant, Helen Matthews, Richard K Wyse, Patrik Brundin, David K Simon, Michael Schwarzschild, David Weiner, Jamie Adams, Charles Venuto, Ted M Dawson, Liana Baker, Melissa Kostrzebski, Tina Ward, Gary Rafalof. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA neurology. vol 78. issue 3. 2021-09-24. PMID:33315105. |
there is a critical need for careful and independent validation of reported symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in parkinson disease (pd). |
2021-09-24 |
2023-08-13 |
Not clear |
| Yun Jung Bae, Jong-Min Kim, Chul-Ho Sohn, Ji-Hyun Choi, Byung Se Choi, Yoo Sung Song, Yoonho Nam, Se Jin Cho, Beomseok Jeon, Jae Hyoung Ki. Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes. Radiology. vol 300. issue 2. 2021-09-24. PMID:34100679. |
parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the midbrain. |
2021-09-24 |
2023-08-13 |
Not clear |
| Octavian Adam, Sharmeen Azher, Edward Valachovic, Amy Hahn, Eric Molh. Narcolepsy genetic marker HLA DQB1*06:02 and excessive daytime sleepiness in Parkinson disease patients treated with dopaminergic agents. Journal of neurology. 2021-09-24. PMID:34559298. |
narcolepsy genetic marker hla dqb1*06:02 and excessive daytime sleepiness in parkinson disease patients treated with dopaminergic agents. |
2021-09-24 |
2023-08-13 |
human |
| Victor A D Holanda, Julia J Didonet, Manara B B Costa, Adriano H do Nascimento Rangel, Edilson D da Silva, Elaine C Gaviol. Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease. Pharmaceuticals (Basel, Switzerland). vol 14. issue 8. 2021-08-31. PMID:34451872. |
parkinson disease (pd) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. |
2021-08-31 |
2023-08-13 |
rat |
| Taiwo G Olubodun-Obadun, Ismail O Ishola, Olufunmilayo O Adeyem. Potentials of autophagy enhancing natural products in the treatment of Parkinson disease. Drug metabolism and personalized therapy. 2021-08-14. PMID:34391219. |
parkinson disease (pd) is a progressive neurodegenerative movement disorder characterized by motor and non-motor symptoms due to loss of striatal dopaminergic neurons and disruption of degradation signaling leading to the formation of lewy bodies (aggregation of α-synuclein). |
2021-08-14 |
2023-08-13 |
Not clear |
| Diego Orcioli-Silva, Rodrigo Vitório, Priscila Nóbrega-Sousa, Victor Spiandor Beretta, Núbia Ribeiro da Conceição, Anderson Souza Oliveira, Marcelo Pinto Pereira, Lilian Teresa Bucken Gobb. Cortical Activity Underlying Gait Improvements Achieved With Dopaminergic Medication During Usual Walking and Obstacle Avoidance in Parkinson Disease. Neurorehabilitation and neural repair. vol 35. issue 5. 2021-07-26. PMID:33754884. |
cortical activity underlying gait improvements achieved with dopaminergic medication during usual walking and obstacle avoidance in parkinson disease. |
2021-07-26 |
2023-08-13 |
Not clear |
| Diego Orcioli-Silva, Rodrigo Vitório, Priscila Nóbrega-Sousa, Victor Spiandor Beretta, Núbia Ribeiro da Conceição, Anderson Souza Oliveira, Marcelo Pinto Pereira, Lilian Teresa Bucken Gobb. Cortical Activity Underlying Gait Improvements Achieved With Dopaminergic Medication During Usual Walking and Obstacle Avoidance in Parkinson Disease. Neurorehabilitation and neural repair. vol 35. issue 5. 2021-07-26. PMID:33754884. |
dopaminergic medication improves gait in people with parkinson disease (pd). |
2021-07-26 |
2023-08-13 |
Not clear |